Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03608241 · ClinicalTrials.gov registry record · Phase 1
A Study TO Estimate THE Effect OF PF-06651600 ON THE Pharmacokinetics (PK) OF Oral Contraceptive (OC)
A Phase 1 study of Healthy Females, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT03608241: Completed Phase 1 study of Healthy Females, sponsored by Pfizer.
NCT03608241 is a Phase 1 study of Healthy Females that has completed, run by Pfizer. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03608241, a Phase 1 study of Healthy Females, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1, randomized, 2 way crossover, multiple dose, open label study of the effect of multiple dose PF-06651600 on single dose OC PK in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences.
Primary Outcome
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).
Conditions Studied
Interventions
- DRUG PF-06651600
- DRUG Ethinyl estradiol (EE) and levonogestrel (LN)
Study Locations (2)
Florida
- Quotient Sciences - Coral Gables
- Quotient Sciences-Miami, Inc. - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2018-11-23 |
| Phase | Phase 1 |
What the finished NCT03608241 record still lists
NCT03608241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Healthy Females appearing as the primary indexed condition, and to 2 interventions - of which PF-06651600 is the first listed.
NCT03608241 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03608241 about?
NCT03608241 is a clinical study titled "A Study TO Estimate THE Effect OF PF-06651600 ON THE Pharmacokinetics (PK) OF Oral Contraceptive (OC)". This is a Phase 1, randomized, 2 way crossover, multiple dose, open label study of the effect of multiple dose PF-06651600 on single dose OC PK in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences.
What is the current status of trial NCT03608241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-09-21. Estimated completion is 2018-11-23.
What conditions does trial NCT03608241 study?
This clinical trial studies the following conditions: Healthy Females.
What interventions are being tested in trial NCT03608241?
The interventions under investigation include: PF-06651600 (DRUG), Ethinyl estradiol (EE) and levonogestrel (LN) (DRUG).
Who is sponsoring clinical trial NCT03608241?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03608241 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Females
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03608241's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI